MIMEDX GROUP, INC.

MiMedx Group, Inc. (NASDAQ: MDXG) is a pioneer and leader in regenerative biomaterial solutions focused on helping humans heal. The company operates through a portfolio of advanced wound care and surgical products derived from human placental tissue, animal-derived xenografts, and complementary wound care modalities. MiMedx's core offerings include EPIFIX, EPICORD, and EPIEFFECT placental allografts for wound care applications, along with AMNIOFIX and related products for surgical use. The company also markets HELIOGEN, its first FDA 510(k)-cleared xenograft product, and distributes complementary products including RegenKit Wound Gel, NovaForm Wound Matrix, G4Derm Plus, and Hydrelix Collagen Matrix through exclusive distribution agreements.

The company manufactures its proprietary placental allograft products using its patented PURION processing technique, which preserves natural growth factors and regulatory proteins while maintaining tissue structure. MiMedx operates manufacturing facilities in Marietta and Kennesaw, Georgia, and has developed an extensive network of hospital partnerships across the United States to source donated placental tissue from consenting mothers. The company's products are used across multiple sites of service including physician offices, wound care centers, hospitals, nursing homes, and federal facilities such as the Department of Veterans Affairs.

MiMedx serves the advanced wound care market, which addresses chronic wounds affecting millions of patients in the United States, and the surgical market, where its products are used in procedures ranging from surgical recovery to tissue protection and reinforcement. The company is expanding internationally, with particular focus on Japan where EPIFIX holds first-mover advantage as the only approved amniotic tissue product for broad wound treatment applications. The company has secured coverage for over 300 million covered lives through private payers and maintains broad Medicare reimbursement for its wound care products. MiMedx holds approximately 82 U.S. patents related to its amniotic tissue technology with nearly 300 issued and pending patents globally. The company's website is www.mimedx.com.